The Value Proposition in Percutaneous Coronary Intervention∗
نویسندگان
چکیده
منابع مشابه
The value proposition in percutaneous coronary intervention.
New therapies are incorporated into clinical practice for a variety of reasons. Usually, they are more efficacious than what is currently used for a specific disease state. Sometimes, they are just as efficacious but safer. When a new treatment strategy is able to achieve better efficacy and safety, at an equal or lower cost, it becomes a “dominant” strategy. Few therapies in cardiovascular med...
متن کاملDynamic changes in purine catabolism in patients with acute coronary syndrome that underwent percutaneous coronary intervention
Background: Cardiovascular diseases are global problems. They are causes of death in about 43% of people worldwide and may become the most widespread reason of death by 2020. The prognosis is directly dependent to immediate diagnosis and on time treatment. Introduction of new biochemical markers as the early diagnosis of complications after coronary revascularization is very important in this p...
متن کاملPrognostic Value of the SYNTAX Score in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
Results Among patients in the first, second, and third SS tertiles, the 1-year rates of mortality were 1.5%, 1.6%, and 4.0%, respectively (p 0.0005); the cardiac mortality rates were 0.2%, 0.9%, and 2.7%, respectively (p 0.0001); the myocardial infarction (MI) rates were 6.3%, 8.3%, and 12.9%, respectively (p 0.0001); and the target vessel revascularization (TVR) rates were 7.4%, 7.0%, and 9.8%...
متن کاملFacilitated percutaneous coronary intervention.
M ultiple, large randomised trials comparing primary percutaneous coronary intervention (PCI) with fibrinolytic therapy for ST elevation myocardial infarction (STEMI) have shown that primary PCI results in lower rates of death, reinfarction, and stroke. Consequently, primary PCI has become the preferred reperfusion strategy for STEMI. Unfortunately, primary PCI is available in only a minority o...
متن کاملBivalirudin in percutaneous coronary intervention
Bivalirudin is a member of the direct thrombin inhibitor group of anticoagulants. It has been evaluated as an alternative to unfractionated and low-molecular-weight heparins in the settings of percutaneous coronary intervention (PCI) and acute coronary syndrome (ACS). Results of clinical trials to date suggest bivalirudin is a viable alternative to the use of a heparin combined with a glycoprot...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JACC: Cardiovascular Interventions
سال: 2013
ISSN: 1936-8798
DOI: 10.1016/j.jcin.2013.06.003